{
    "clinical_study": {
        "@rank": "23404", 
        "arm_group": [
            {
                "arm_group_label": "Probiotics", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the tolerability and effect of a probiotic product, when co-administered with\n      antibiotics, on the incidence and duration of loose/watery stools following the antibiotic\n      treatment in children."
        }, 
        "brief_title": "Efficacy and Safety of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders.", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Antibiotic-associated Loose/Watery Stools", 
        "condition_browse": {
            "mesh_term": [
                "Diarrhea", 
                "Digestive System Diseases", 
                "Gastrointestinal Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          1. Children at the age of 1-11 years that have been ordinated to start antibiotic\n             treatment except for penicillin.\n\n          2. Possibility to initiate the probiotic treatment within 24 hours after the first dose\n             of the antibiotic treatment.\n\n          3. Children whose parents or legal caregivers have signed the informed consent to\n             participate in the study.\n\n        Exclusion criteria\n\n          1. Chronic intestinal disease.\n\n          2. Current immunodeficiency or immunosuppressive treatment.\n\n          3. Chronic or acute diarrhoeal disease.\n\n          4. Use of laxatives the week before inclusion in the study.\n\n          5. Antibiotic treatment for the last four weeks before inclusion in the study.\n\n          6. Known hypersensitivity to any of the ingredients in the probiotic product or the\n             placebo [potato starch, silicon dioxide, capsule (hypromellose, water) \u00b1 bacterial\n             culture].\n\n          7. Intake of any probiotic products for the last two weeks before inclusion in the\n             study.\n\n          8. Patient requiring hospitalisation. Lack of parents\u00b4/legal guardians\u00b4 informed\n             consent."
            }, 
            "gender": "Both", 
            "maximum_age": "11 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940913", 
            "org_study_id": "ProAAD"
        }, 
        "intervention": [
            {
                "arm_group_label": "Probiotics", 
                "intervention_name": "Probiotic capsules", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo capsules", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Warsaw", 
                    "country": "Poland"
                }, 
                "name": "Multicenter study at 13 health care centers in Warsaw"
            }
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Poland: Ethics Committee"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Reduction of the incidence of loose/watery stools following antibiotic treatment in children.", 
            "safety_issue": "No", 
            "time_frame": "19-24 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940913"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Probi AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Probi AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}